Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$9.3 million.

  • Arcturus Therapeutics Holdings' Change in Receivables fell 25134.12% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year decrease of 17737.19%. This contributed to the annual value of -$28.1 million for FY2024, which is 19587.03% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Change in Receivables is -$9.3 million, which was down 25134.12% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Change in Receivables ranged from a high of $89.7 million in Q1 2023 and a low of -$89.7 million during Q2 2023
  • Over the past 5 years, Arcturus Therapeutics Holdings' median Change in Receivables value was -$118000.0 (recorded in 2021), while the average stood at $306631.6.
  • Over the last 5 years, Arcturus Therapeutics Holdings' Change in Receivables had its largest YoY gain of 2759104.94% in 2023, and its largest YoY loss of 611080.33% in 2023.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Change in Receivables stood at $1.4 million in 2021, then plummeted by 46.75% to $720000.0 in 2022, then crashed by 955.0% to -$6.2 million in 2023, then plummeted by 326.01% to -$26.2 million in 2024, then skyrocketed by 64.72% to -$9.3 million in 2025.
  • Its last three reported values are -$9.3 million in Q3 2025, $2.6 million for Q2 2025, and $10.6 million during Q1 2025.